CD4 and neoplasm: Subsequently, antibody therapy increased the CD8+ T-cell:Treg ratio in the tumor without further augmentation from peritumorally administered DR-BMCs, but tritherapy significantly increased the ratio of tumor CD4+ Teffs:Tregs compared to all other groups (Fig. 3d).